logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical appoints Edward James Henderson as the public officer and director of its Australia) subsidiary

Henderson is HLB Mann Judd's managing partner, Business Advisory Services, Tax Consulting, Brisbane, Queensland, Australia

PreveCeutical Medical Inc. -
PreveCeutical said he is a respected business strategist with an extensive range of expertise and knowledge across a multitude of industries

PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) has announced the appointment of Edward James Henderson as the public officer and director of its PreveCeutical (Australia) Pty Ltd. subsidiary with immediate effect.

The group noted that Henderson is HLB Mann Judd's managing partner, Business Advisory Services, Tax Consulting, Brisbane, Queensland, Australia.

It added that he is a respected business strategist with an extensive range of expertise and knowledge across a multitude of industries.

READ: PreveCeutical says current stage of analgesic research program soon to complete

In a statement, Stephen Van Deventer, PreveCeutical's chief executive officer, commented: "We are very pleased and fortunate to have James join our Board of Directors and take the role of Public Officer with our Subsidiary.

“Having a board member and Public Officer of his calibre and Australian expertise will be very valuable to the Company, especially at this time when we are transitioning from research to development and commercialization."

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

The company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

Contact the author at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.06 CAD

CSE:PREV
Market: CSE
Market Cap: $23.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

3 weeks, 2 days ago

2 min read